NASDAQ$OMCL
Omnicell Inc. · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported third quarter earnings, with GAAP net income per diluted share of $0.20 and non-GAAP net income per diluted share of $0.60.
Omnicell reported solid financial performance in Q3 2020, exceeding the high end of guidance ranges. The company saw increased new customer wins and bookings, particularly with the top 300 U.S. health systems.
- GAAP revenues for the third quarter of 2020 were $213.7 million, down 6.6% from the third quarter of 2019.
- GAAP net income for the third quarter of 2020 was $8.8 million, or $0.20 per diluted share, compared to $20.0 million, or $0.46 per diluted share, for the third quarter of 2019.
- Non-GAAP revenues for the third quarter of 2020 were $213.7 million, down 6.6% from the third quarter of 2019.
- Non-GAAP net income for the third quarter of 2020 was $26.2 million, or $0.60 per diluted share, compared to $32.7 million, or $0.76 per diluted share, for the third quarter of 2019.
Headline financials
Revenue & EPS history
Omnicell · Revenue · Quarterly
$214M
Revenue by segment
Omnicell · $151M total across 1 segment · Q3 2020
- Product revenues$151M—100.0%
Forward guidance
For the fourth quarter of 2020, the Company expects non-GAAP total revenues to be between $238 million and $244 million and non-GAAP earnings to be between $0.72 and $0.77 per share.
Tailwinds
- Non-GAAP total revenues to be between $238 million and $244 million.
- Non-GAAP product revenues to be between $165 million and $170 million.
- Non-GAAP service revenues to be between $73 million and $74 million.
- Non-GAAP earnings to be between $0.72 and $0.77 per share.
- 2021 preliminary non-GAAP total revenues to range between $1.015 billion and $1.045 billion.
Headwinds
- Bookings and revenue in future periods could be impacted if hospitals need to materially change their operations in order to address a continued increase in COVID-19 cases.
- Health systems have faced increased costs, decreased revenues and cash flow challenges due to cancelled or postponed elective procedures and other reduced demand.
- Customers to delay or defer purchasing decisions and/or implementation of our solutions during the first half of 2020, which resulted in delayed implementations and lower product bookings compared to management’s expectations prior to the COVID-19 outbreak.
- The full impact of the COVID-19 pandemic and related containment measures cannot be predicted and to date, the COVID-19 pandemic and related containment measures have adversely affected and may continue to adversely affect, perhaps materially, our business, results of operations, financial condition, and liquidity.
- We cannot predict how long the pandemic and measures intended to contain the spread of COVID-19 will continue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+0.7%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+4.7%
Avg return
30 days after
55%
36 / 65 earnings
Positive
+34.3%
Q2 2024
Best reaction
-29.4%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.2% | +13.7% | +18.8% | |
| Q4 2025 | -16.3% | -16.5% | -11.5% | |
| Q3 2025 | +13.4% | +16.7% | +23.5% | |
| Q1 2025 | -16.0% | -15.4% | +1.2% | |
| Q4 2024 | -11.2% | -7.1% | -16.7% | |
| Q3 2024 | +21.2% | +20.9% | +16.1% | |
| Q2 2024 | +34.3% | +41.6% | +52.3% | |
| Q1 2024 | +10.9% | +11.5% | +19.9% | |
| Q4 2023 | -15.6% | -11.9% | -12.0% | |
| Q3 2023 | -14.9% | -13.9% | -5.5% | |
| Q2 2023 | +2.3% | +2.9% | -10.0% | |
| Q1 2023 | +8.9% | +7.1% | +18.6% | |
| Q4 2022 | +7.9% | +6.6% | +6.4% | |
| Q3 2022 | -29.4% | -35.9% | -33.4% | |
| Q2 2022 | -2.1% | -5.6% | -10.6% | |
| Q1 2022 | +1.2% | +5.9% | +4.7% | |
| Q4 2021 | -9.6% | -18.4% | -11.5% | |
| Q3 2021 | +2.2% | +1.6% | +1.5% | |
| Q2 2021 | -1.1% | +0.4% | +7.1% | |
| Q1 2021 | +1.8% | -1.5% | -2.4% | |
| Q4 2020 | +7.0% | +8.9% | +6.5% | |
| Q3 2020 | +2.3% | +2.9% | +27.0% | |
| Q2 2020 | +9.1% | +5.5% | +2.7% | |
| Q1 2020 | -6.1% | -12.3% | -0.5% | |
| Q4 2019 | -1.4% | +2.3% | -4.5% | |
| Q3 2019 | -3.7% | -1.9% | +7.4% | |
| Q2 2019 | +6.7% | +5.4% | +0.6% | |
| Q1 2019 | +0.7% | +3.8% | +4.7% | |
| Q4 2018 | +17.9% | +21.0% | +28.0% | |
| Q3 2018 | +6.1% | +15.2% | +18.8% | |
| Q2 2018 | +13.7% | +13.0% | +29.5% | |
| Q1 2018 | +1.6% | -0.1% | +5.3% | |
| Q4 2017 | -6.2% | -9.8% | -12.9% | |
| Q3 2017 | -6.4% | -8.2% | -7.6% | |
| Q2 2017 | +12.5% | +16.3% | +12.1% | |
| Q1 2017 | -3.2% | -1.7% | +0.0% | |
| Q4 2016 | -0.7% | +1.0% | +4.5% | |
| Q3 2016 | -6.3% | -6.8% | +3.2% | |
| Q2 2016 | +6.8% | +4.7% | +3.4% | |
| Q1 2016 | +3.9% | — | — | |
| Q4 2015 | -1.0% | — | — | |
| Q3 2015 | -10.5% | — | — | |
| Q2 2015 | -8.8% | — | — | |
| Q1 2015 | -2.6% | — | — | |
| Q4 2014 | +5.3% | — | — | |
| Q3 2014 | +9.7% | — | — | |
| Q2 2014 | -3.9% | — | — | |
| Q1 2014 | +0.4% | — | — | |
| Q4 2013 | +8.9% | — | — | |
| Q3 2013 | -1.4% | — | — | |
| Q2 2013 | +8.7% | — | — | |
| Q1 2013 | +7.6% | — | — | |
| Q3 2010 | -1.3% | — | — | |
| Q4 2012 | +13.4% | — | — | |
| Q3 2012 | +12.2% | — | — | |
| Q2 2012 | +0.9% | — | — | |
| Q1 2011 | -0.3% | — | — | |
| Q1 2012 | +4.8% | — | — | |
| Q4 2011 | +2.6% | — | — | |
| Q4 2009 | +2.6% | — | — | |
| Q3 2011 | -0.7% | — | — | |
| Q2 2010 | -16.9% | — | — | |
| Q2 2011 | -16.9% | — | — | |
| Q4 2010 | -16.9% | — | — | |
| Q1 2010 | +7.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro